Herbert Master
Cardiovascular Disease · Shreveport, LANPI 1225009764
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 55 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 17.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $849 and has fallen 98.3% since, to $14 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in LA, where the typical reported total is $3,225.
Across 55 payments — averaging $18.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$180
- Johnson & Johnson$121
- Edwards Lifesciences$121
- Akcea Therapeutics, Inc.$81
- Amgen$73
- Boehringer Ingelheim$73
- plus $365 from 15 others
What the payments were for
- Food & beverage$1,014100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 12 | $180 |
| Johnson & Johnson | 10 | $121 |
| Edwards Lifesciences | 1 | $121 |
| Akcea Therapeutics, Inc. | 4 | $81 |
| Amgen | 3 | $73 |
| Boehringer Ingelheim | 5 | $73 |
| Atricure, Inc. | 1 | $67 |
| E.r. Squibb & Sons, L.L.C. | 4 | $53 |
| Philips North America LLC | 1 | $39 |
| Abiomed | 2 | $34 |
| Arbor Pharmaceuticals, Inc. | 2 | $27 |
| Lundbeck LLC | 1 | $24 |
| Preventice Services, LLC | 1 | $21 |
| Irhythm Technologies, Inc. | 1 | $14 |
| Actelion Pharmaceuticals US, Inc. | 1 | $14 |
| Cycle Pharmaceuticals Inc | 1 | $14 |
| Pfizer | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $12 |
| Regeneron Healthcare Solutions, Inc. | 1 | $11 |
| Astellas Pharma US Inc | 1 | $11 |
| Bardy Diagnostics, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,014 in reported general payments places this provider in the 30th percentile of 281 cardiovascular disease providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Telmisartan | 12 | $746 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Shreveport
- Basel KasabaliShreveport$30K
- Tina FirouzbakhtShreveport$28K
- Wenwu ZhangShreveport$21K
- William EavesShreveport$15K
- Jagan BeedupalliShreveport$13K
- Mahin KhanShreveport$10K
- Keith FerdinandNew Orleans$239K
- Carl LavieNew Orleans$228K
- Imran ChaudryMonroe$202K
- Corey FosterLake Charles$158K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.